ZEGERID OTC™ Hits Store Shelves; Offers Only Patented Dual-Ingredient Option for 24 Hour Frequent Heartburn Relief without a Prescription
WHITEHOUSE STATION, NJ, April 1, 2010 – Merck & Co., Inc. announced that beginning
today, ZEGERID OTC™ (omeprazole 20 mg/sodium bicarbonate 1100 mg capsules), a new
over-the-counter (OTC) option for treating frequent heartburn without a prescription, will become
available in drug stores, grocery stores, mass merchandisers and club stores nationwide. The
only OTC proton pump inhibitor (PPI) product with two active ingredients, ZEGERID OTC
delivers relief in a different way. ZEGERID OTC has a patented dual-ingredient formula that
combines omeprazole, the leading prescription acid-reducing medicine, and sodium
bicarbonate, which protects the omeprazole in this product from acid in the stomach and allows
Approved by the U.S. Food and Drug Administration in December 2009 for over-the-
counter use, ZEGERID OTC capsules will be offered in their original 20 mg prescription strength
formula. Proton pump inhibitors such as ZEGERID OTC are the strongest and most effective
class of acid-reducing medication available for the 50 million Americans who suffer from
frequent heartburn, defined as heartburn that occurs two or more days a week. ZEGERID OTC
treats frequent heartburn by controlling and suppressing acid for a full 24 hours, all day and all
night. As with all PPI products, ZEGERID OTC may take 1 to 4 days for full effect, although
some people get complete relief of symptoms within 24 hours.
“To date, all other OTC PPIs have used an enteric coating to prevent the medicine from
being broken down by acid in the stomach prior to absorption,” explained Dr. Michael Rahmin, a
prominent gastroenterologist at The Valley Hospital in Ridgewood, New Jersey and one of
Castle Connol y’s 2009 Top Doctors in the New York Metro Area. “ZEGERID OTC capsules do
not need an enteric coating, because the sodium bicarbonate offers built-in protection against
stomach acid, so the omeprazole can be absorbed by the body and get to work treating frequent
ZEGERID OTC is a 14-day course of treatment taken once per day to treat frequent
heartburn as directed and, if needed, may be repeated every 4 months. For more information
about ZEGERID OTC, visit www.ZegeridOTC.com.
“With its strong history as an effective prescription product, we are excited to bring
ZEGERID OTC directly to consumers,” said Bridgette P. Heller, President, Schering-
Plough Consumer HealthCare. “Our Consumer HealthCare division is already home to a variety
of industry leading OTC products, including CLARITIN, DR. SCHOLL’S, MiraLAX, AFRIN and
LOTRIMIN. We are confident that ZEGERID OTC will quickly join this list of highly regarded
ZEGERID OTC is being marketed over-the-counter by Schering-Plough HealthCare
Products, Inc., the consumer healthcare subsidiary of Merck & Co., Inc. Under an agreement
with Santarus, a specialty biopharmaceutical company that developed and currently markets
prescription ZEGERID®, Schering-Plough HealthCare Products is responsible for the
development, manufacturing and commercialization of ZEGERID OTC products for frequent
Santarus will continue to manufacture, promote and sell its prescription ZEGERID
(omeprazole/sodium bicarbonate) products in both 20 mg and 40 mg dosage strengths in the
US. For additional information on prescription ZEGERID, please visit www.Zegerid.com.
About Schering-Plough Consumer HealthCare
Today's Merck is working to help the world be well. Schering-Plough Consumer HealthCare is a
subsidiary of Merck & Co., Inc. Each day, millions count on one or more of our industry-leading
brands that help prevent or treat various common conditions. These include household names
such as CLARITIN for allergies, COPPERTONE for sun care, DR. SCHOLL'S for foot care, and
many more. Merck. Be well. For more information, visit
Forward-Looking Statement
This news release includes “forward-looking statements” within the meaning of the safe harbor
provisions of the United States Private Securities Litigation Reform Act of 1995. Such
statements may include, but are not limited to, statements about the benefits of the merger
between Merck and Schering-Plough, including future financial and operating results, the
combined company’s plans, objectives, expectations and intentions and other statements that
are not historical facts. Such statements are based upon the current beliefs and expectations of
Merck’s management and are subject to significant risks and uncertainties. Actual results may
differ from those set forth in the forward-looking statements.
The following factors, among others, could cause actual results to differ from those set forth in
the forward-looking statements: the possibility that the expected synergies from the merger of
Merck and Schering-Plough will not be realized, or will not be realized within the expected time
period, due to, among other things, the impact of pharmaceutical industry regulation and
pending legislation that could affect the pharmaceutical industry; the risk that the businesses will
not be integrated successfully; disruption from the merger making it more difficult to maintain
business and operational relationships; Merck’s ability to accurately predict future market
conditions; dependence on the effectiveness of Merck’s patents and other protections for
innovative products; the risk of new and changing regulation and health policies in the U.S. and
internationally and the exposure to litigation and/or regulatory actions.
Merck undertakes no obligation to publicly update any forward-looking statement, whether as a
result of new information, future events or otherwise. Additional factors that could cause results
to differ materially from those described in the forward-looking statements can be found in
Merck’s 2009 Annual Report on Form 10-K and the company’s other filings with the Securities
and Exchange Commission (SEC) available at the SEC’s Internet site
Manager Report Franklin Templeton Investment Funds Franklin Income Fund For Professional investor use only. Not to be distributed to retail investors. Fund Characteristics Overview • U.S. equity indexes delivered mixed returns in November as investor fears intensified about whether a bipartisan deal could be struck to avert the impending 2013 “fiscal cliff” of tax hi
Estado do Amazonas Prefeitura Municipal de Apuí Comissão Municipal de Licitação CARTA CONTRATO Nº. 108/2013. CARTA CONTRATO, para AQUISIÇÃO DE MEDICAMENTOS E MATERIAIS DE LABORATÓRIO, destinados ao atendimento da população do Município de Apuí, na forma abaixo: Aos 02 (dois) dias do mês de Setembrodo ano de dois mil e treze, o Município de apuí, inscrit